You are here

US government shifts US$81m to Zika vaccine research

Friday, August 12, 2016 - 09:49
38897564 - 29_06_2016 - US-NATIONAL-PRIMATE-RESEARCH-CENTERS-STUDY-ZIKA-VIRUS.jpg
The US Department of Health and Human Services has shifted US$81 million in funds from other projects to continue work on developing vaccines to fight Zika in the absence of any funding from US lawmakers.

[CHICAGO] The US Department of Health and Human Services has shifted US$81 million in funds from other projects to continue work on developing vaccines to fight Zika in the absence of any funding from US lawmakers.

In a letter addressed to Nancy Pelosi, a Democrat and minority leader of the US House of Representatives, HHS Secretary Sylvia Burwell said she was allocating US$34 million in funding to the National Institutes of Health and US$47 million to the Biomedical Advanced Research and Development Authority (Barda) to work on Zika vaccines.

Ms Burwell said the funding was intended to keep Zika vaccine research going despite the lack of funding from US lawmakers, who left for summer recess before allocating any funding to Zika research and preparedness.

The mosquito-borne Zika virus has spread to more than 50 countries and territories since the outbreak began last year in Brazil. On Thursday, governor Rick Scott said state health officials have identified three additional people in the affected area with locally transmitted Zika, bringing the total to 25.

The Obama administration in February requested US$1.9 billion to fight Zika, but congressional lawmakers have been considering a much smaller sum. A bill providing US$1.1 billion was blocked by Democrats after Republicans attached language to stop abortion-provider Planned Parenthood from using that government funding for healthcare services, mainly in US territories like Puerto Rico.

The Republican legislation also would siphon off unused money under President Barack Obama's signature 2010 healthcare law to combat Zika. In addition, Democrats balked at a Republican provision that they said would gut clean water protections.

The new bolus of funds from HHS comes on top of the US$589 million in repurposed funds previously allocated for Ebola efforts. HHS has said these funds will run out at the end of August.

At a press briefing in Washington, Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he needs US$33 million to prepare to move the first potential Zika vaccine to the second phase of human clinical trials. The first phase of that testing is expected to end in late November or December.

Mr Fauci said the health secretary has the authority to transfer one per cent of NIH's US$33 billion budget per year from one Institute to the other. He said the director of the NIH, Dr Francis Collins, will decide which existing programs the funds will be drawn from.

"He will probably do it on a prorated basis across the Institutes," he said.

Mr Fauci said the budget transfer will not fill the longer-term NIH funding needs to fight the virus and to develop a second or third potential vaccine candidate. Drugs frequently fail to realise the promise they show in early trials. "We still need about US$196 million more," he said.

Mr Fauci said the health secretary's action was essentially one of desperation given the failure of Congress to authorise additional funding.

Taking money from other research programs "is extremely damaging to the biomedical research enterprise," he said.

"We're taking money away from cancer, diabetes, all those things."

Dr LaMar Hasbrouck, executive director of the National Association of County and City Health Officials, said at the briefing that local health authorities are similarly siphoning off money from other programs.

"We're robbing Peter to pay Paul," he said.

In her letter, Burwell said the US$47 million in funding for Barda will allow the agency to enter into contracts with key partners to develop vaccines. But, she said Barda will need an estimated US$342 million in additional funding to continue its work with outside partners in the development of vaccines, diagnostics and pathogen inactivation technology used to protect the US blood supply.

REUTERS

For all our Zika coverage, go to bt.sg/zika